Announcements Trials

Browse Landscape

Phase

Phase 2 8 Phase EARLY_PHASE1 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Lymphoma, B-Cell 1

Interventions

pembrolizumab 213 Cyclophosphamide 123 Nivolumab 110 Carboplatin 94 fludarabine 81 Gemcitabine 78 Specimen Handling 74 Bevacizumab 73 Injections 71 venetoclax 70 Magnetic Resonance Spectroscopy 67 Dexamethasone 66 Paclitaxel 64 Biopsy 59 atezolizumab 56 Cisplatin 54 Ipilimumab 50 Temozolomide 46 Lenalidomide 43 Azacitidine 43 Docetaxel 42 Pemetrexed 41 Rituximab 40 Radiotherapy 40 Oxaliplatin 40 Fluorouracil 39 Cetuximab 38 durvalumab 37 Cytarabine 36 Capecitabine 36

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × brexucabtagene autoleucel × 1 year × Clear all

NCT02625480 2026-04-09

ZUMA-4

Gilead Sciences

Phase 1/2 Completed

Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡